Development of a T-Cell Receptor Mimic Antibody Against Wild-Type P53 for Cancer Immunotherapy

Cancer Research - United States
doi 10.1158/0008-5472.can-16-3247
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

T-Cell Engineering by a Chimeric T-Cell Receptor With Antibody-Type Specificity for the HIV-1 Gp120

Gene Therapy
Molecular MedicineGeneticsMolecular Biology
2004English

An Introduction to Chimeric Antigen Receptor (CAR) T Cell Immunotherapy for Human Cancer

American Journal of Hematology
Hematology
2019English

Hurdles of CAR-T Cell-Based Cancer Immunotherapy Directed Against Solid Tumors

Science China Life Sciences
GeneticsMolecular BiologyEnvironmental ScienceBiochemistryBiological SciencesAgricultural
2016English

Chimaeric Antigen Receptor T-Cell Therapy for Tumour Immunotherapy

Bioscience Reports
BiochemistryCell BiologyMolecular BiologyBiophysics
2017English

Development of Next Generation Antibody-Based Immunotherapy for Childhood Cancer Neuroblastoma

The Lancet
Medicine
2016English

Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy

JAMA Oncology
Cancer ResearchOncology
2018English

CD4+ T Cell Responses to HLA-DP5-restricted Wild-Type Sequence P53 Peptides in Patients With Head and Neck Cancer

Cancer Immunology, Immunotherapy
Cancer ResearchMedicineOncologyAllergyImmunology
2009English

IL15 and T-Cell Stemness in T-Cell-Based Cancer Immunotherapy

Cancer Research
Cancer ResearchOncology
2015English

Chimeric Antigen Receptor T-Cell Immunotherapy for Glioblastoma: Practical Insights for Neurosurgeons

Neurosurgical Focus
MedicineSurgeryNeurology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy